bioAffinity Technologies Commences ~$4M Offering Of Common Stock At $6.122 Per Share

bioAffinity Technologies, Inc. has announced a registered direct offering of common stock, aiming to raise approximately $4 million at a price of $6.122 per share. The proceeds will be used for working capital and to support the expected growth in sales of its noninvasive lung cancer test, CyPath® Lung. The offering is conducted under Nasdaq rules and involves an institutional investor.